MARKET

OCUL

OCUL

Ocular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.25
0.00
0.00%
Pre Market: 8.35 +0.1 +1.21% 08:40 07/02 EDT
OPEN
--
PREV CLOSE
8.33
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
9.24
52 WEEK LOW
2.460
MARKET CAP
517.88M
P/E (TTM)
-4.3058
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OCUL stock price target is 10.50 with a high estimate of 15.00 and a low estimate of 3.000.

EPS

OCUL News

More
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 6d ago
FDA rejects Allergan application for wet AMD drug
Seeking Alpha - Article · 6d ago
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16)
Benzinga · 06/16 12:15
Edited Transcript of OCUL.OQ earnings conference call or presentation 8-May-20 12:30pm GMT
Thomson Reuters StreetEvents · 06/15 23:38
Ocular Therapeutix to Hold Virtual 2020 Annual Meeting Of Stockholders
Business Wire · 06/15 21:01
Ocular Therapeutix Highlights Presentation Of Data At Association For Research In Vision, Ophthalmology Meeting
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple
Benzinga · 06/15 12:13
Ocular Therapeutix™ to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the Association fo
Business Wire · 06/15 12:00

Industry

Medical Equipment, Supplies & Distribution
+0.63%
Healthcare Equipment & Supplies
+0.48%

Hot Stocks

Symbol
Price
%Change

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
More

Webull offers kinds of Ocular Therapeutix Inc stock information, including NASDAQ:OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.